Page last updated: 2024-08-26

bosentan anhydrous and Sclerosis, Systemic

bosentan anhydrous has been researched along with Sclerosis, Systemic in 164 studies

Research

Studies (164)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	75 (45.73)	29.6817
2010's	80 (48.78)	24.3611
2020's	9 (5.49)	2.80

Authors

Authors	Studies
Isomoto, H; Kimura, R; Sugihara, T; Sugita, K; Yamamoto, O	1
Endo, Y; Ishikawa, M; Motegi, SI; Sekiguchi, A; Uchiyama, A; Yamazaki, S	1
Allanore, Y; Alunno, A; Baron, M; Campochiaro, C; Chung, L; Denton, CP; Distler, O; Frech, T; Furst, DE; Giuggioli, D; Hughes, M; Khanna, D; Krieg, T; Kuwana, M; Maltez, N; Matucci-Cerinic, M; Moinzadeh, P; Pope, J; Ross, L; Schoones, JW; Suliman, YA	1
Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A	1
Abdulle, AE; Mulder, DJ; van Roon, AM	1
Berry-Cabán, CS; Black, L; De Blasio, DC; Huh, J; Tracy, CL	1
Casademont, J; Castellví, I; Corominas, H; Fonollosa, V; Sarmiento, M; Simeón, CP	1
Ju, JH; Kim, BY; Kim, HS; Kim, SH; Kim, YS; Lee, KA; Park, S; Son, CN	1
Fontaine, C; Jaquinandi, V; Mahe, G; Omarjee, L	1
Abuowda, Y; Almeida, RS; Matos-Costa, J; Oliveira, AA; Pego, P; Santos, C	1
Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Sulli, A	1
Botella, A; Moniz, P; Rei, D; Rodrigues, J	1
Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA	1
Asano, Y; Fukui, Y; Hirabayashi, M; Miura, S; Miyagawa, T; Nakamura, K; Saigusa, R; Sato, S; Yamashita, T; Yoshizaki, A	1
Gøransson, LG; Norheim, KB; Vikse, J	1
Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Moggi-Pignone, A; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA	1
Autenrieth, J; Bert, C; Riemekasten, G; Worm, M	1
Burns, A; Chakravarty, K; Denton, CP; Khan, K; Ong, VH; Penn, H; Quillinan, N	1
Deray, G; Izzedine, H; Rouvier, P	1
Catarsi, E; Doveri, M; Tavoni, A	1
Belperio, JA; Fishbein, MC; Lynch, JP; Saggar, R	1
Aoyagi, K; Kawakami, A; Kawashiri, SY; Terada, K; Ueki, Y; Yamasaki, S	1
Romaniello, A; Rosato, E; Salsano, F; Viola, G	1
Bölke, E; Buhren, BA; Gerber, PA; Hetzer, S; Homey, B; Kammers, K; Meller, S; Schrumpf, H	1
Denton, CP; Ngcozana, T; Ong, V	1
Cimmino, M; Cutolo, M; Paolino, S; Pizzorni, C; Ravera, F; Ruaro, B; Seriolo, B; Smith, V; Sulli, A; Zampogna, G	1
Akamata, K; Aozasa, N; Asano, Y; Ichimura, Y; Noda, S; Sato, S; Takahashi, T; Taniguchi, T; Toyama, T	1
Agard, C; Bérezné, A; Carpentier, PH; Chatelus, E; Clerson, P; Diot, E; Gressin, V; Hachulla, E; Jego, P; Lok, C; Mouthon, L; Quéré, I; Sibilia, J; Sparsa, A; Van Kien, AK	1
Glukhova, SI; Iudkina, NN; Kurmukov, IA; Nasonov, EL; Nikolaeva, EV; Volkov, AV	1
Corkill, MM; Ghosh, SK; Hart, HH; Ng, KP	1
Bloemsaat-Minekus, JP; Meijs, J; Vonk, MC; Voskuyl, AE	1
Belz, D; Hunzelmann, N; Moinzadeh, P	1
Alessandri, E; Brizzolara, R; Cutolo, M; Montagna, P; Pizzorni, C; Smith, V; Soldano, S; Sulli, A; Tavilla, PP; Villaggio, B	1
Akamata, K; Asano, Y; Ichimura, Y; Noda, S; Sato, S; Takahashi, T; Taniguchi, T; Toyama, T; Trojanowska, M; Yamashita, T	1
Kinoshita, H; Yoshifuji, H	1
Glukhova, SI; Kurmukov, IA; Nikolaeva, EV; Volkov, AV; Yudkina, NN	1
Asano, Y	1
Alessandro, B; Andrea, O; Antonio, P; Claudio, L; Daniela, R; Elisa, T; Federico, C; Giacomo, M; Giuseppe, A; Giuseppe, P; Mariaelisa, R; Marzia, D; Ruggero, B	1
di Serio, F; Iannone, F; Lapadula, G; Nivuori, M; Praino, E; Rotondo, C	1
Sharabi, I; Tanay, A; Zandman-Goddard, G	1
Asano, Y; Ichimura, Y; Miyagaki, T; Saigusa, R; Sato, S; Sugaya, M; Takahashi, T; Taniguchi, T; Toyama, T; Yamashita, T; Yoshizaki, A	1
Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; De Paulis, A; Guiducci, S; Lepri, G; Matucci-Cerinic, M; Radicati, A	1
Bernal, M; De Cata, A; De Cosmo, S; Inglese, M; Mazzoccoli, G; Molinaro, F; Rubino, R	1
Cannarile, F; Cestelli, V; Ferri, C; Giuggioli, D; Manfredi, A; Praino, E; Sebastiani, M	1
Asano, Y; Endo, H; Hamaguchi, Y; Ihn, H; Kawaguchi, Y; Kuwana, M; Motegi, SI; Sumida, T; Takehara, K; Tanaka, S	1
Beissert, S; Distler, JH; Kreuter, A; Müller-Ladner, U; Riemekasten, G	1
Amoroso, D; Barbano, B; Di Paolo, M; Gigante, A; Palange, P; Romaniello, A; Rosato, E; Tallerini, G	1
Chirico, C; Corallo, C; Cutolo, M; Giordano, N; Kahaleh, B; Montella, A; Nuti, R; Pecetti, G; Soldano, S	1
Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Smith, V; Sulli, A; Trombetta, AC	1
Agard, C; Bérezné, A; Carpentier, PH; Clerson, P; Diot, E; Duval-Modeste, AB; Gressin, V; Hachulla, E; Jego, P; Lok, C; Mouthon, L; Puzenat, E; Richard, MA; Sparsa, A; Van Kien, AK	1
Blaise, S; Cracowski, JL; Forli, A; Imbert, B; Roustit, M	1
Heresi, GA; Minai, OA	1
Coghlan, G; Kabunga, P	1
Langevitz, P; Shalev, L; Zandman-Goddard, G	1
Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Settas, L	1
Silver, RM	1
Matucci-Cerinic, M; Seibold, JR	1
Ferreira, ME; Scheinberg, MA	1
Funauchi, M; Hino, S; Kinoshita, K; Kishimoto, K; Nagare, Y; Shimazu, H; Yano, T	1
Favre, J; Henry, JP; Lallemand, F; Marie, I; Richard, V; Solans, V; Thuillez, C	1
Agard, C; Haloun, A; Hamidou, MA	1
Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A	1
Caruso, C; Giovannetti, A; Pierdominici, M; Romano, A; Rosato, E; Salsano, F	1
Dwyer, N; Jones, G; Kilpatrick, D	1
Fujimoto, M; Hamaguchi, Y; Hasegawa, M; Matsushita, T; Takehara, K	1
Denton, CP; Matucci-Cerinic, M; Pope, JE; Steen, V	1
Coghlan, G; Humbert, M; McLaughlin, V; Nash, P; Steen, V	1
Guillevin, L	3
Alamanos, Y; Argyriou, E; Botzoris, V; Drosos, AA; Tsifetaki, N; Zioga, A	1
Dhillon, S	1
Wimmersberger, Y; Zuercher, D	1
Achouh, L; Humbert, M; Jais, X; Launay, D; Le Pavec, J; Parent, F; Savale, L; Simonneau, G; Sitbon, O; Tchérakian, C; Yaïci, A	1
Bambara, LM; Biasi, D; Caramaschi, P; Mahamid, H	1
Eisendle, K; Gruber, I; Hugl, B; Nguyen, VA; Reider, D; Reider, N	1
Felder, G; Gensch, K; Haust, M; Kuhn, A; Ohmann, C; Ruland, V; Ruzicka, T; Verde, P; Weber, R	1
Allanore, Y; Isvy, A; Kahan, A; Maury, E; Moachon, L	1
Black, CM; Chadha-Boreham, H; Charef, P; Denton, CP; Emery, P; Furst, DE; Guillevin, L; Matucci Cerinic, M; Riemekasten, G; Roux, S; Rubin, LJ; Seibold, JR; Wells, A	1
Bredemeier, M	1
Black, CM; Carpentier, P; Denton, CP; Doyle, MK; Fessler, BJ; Furst, DE; Hellmich, B; Hsu, VM; Korn, JH; Kramer, F; Matucci-Cerinic, M; Mayes, MD; Medsger, TA; Merkel, PA; Morganti, A; Pope, JE; Seibold, JR; Sweiss, NJ; Wigley, FM	1
Borghese, F; Molinaro, I; Pisarri, S; Rosato, E; Rossi, C; Salsano, F	1
Pope, J; Zelenietz, C	1
Aihara, K; Akaike, M; Dagvasumberel, M; Hirata, Y; Iwase, T; Koshiba, K; Kusunose, K; Matsumoto, T; Niki, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yoshida, S	1
Gocho, K; Homma, S; Kusano, E; Ota, H; Sugino, K; Takai, Y	1
Enk, A; Hartmann, M; Hartschuh, W; Haust, M; Klein, S; Krammer, PH; Kretz, CC; Kuhn, A; Oberle, N; Ruland, V; Stumpf, C; Suri-Payer, E	1
Lambova, S; Müller-Ladner, U	1
Botzoris, V; Drosos, AA	1
Derk, CT; Shetty, N	1
Bakx, R; Dogan, K; Klemm, PL	1
Aihara, K; Akaike, M; Iwase, T; Matsumoto, T; Sata, M; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S	1
Pope, J; Walker, KM	1
Alegre Sancho, JJ; Castillo, MJ; Egurbide, MV; Fonollosa, V; Lloria, X; Roman Ivorra, JA; Simeon, CP	1
Belamarich, PF; Ilowite, NT; Kenney-Riley, KM; Wahezi, DM	1
Hashida, Y; Nakayama, Y; Ohta, K; Saito, T; Shimizu, M; Takehara, K; Ueno, K; Yachie, A; Yokoyama, T	1
Brodmann, M; Froehlich, H; Hafner, F; Steidl, K; Thomas, G	1
Hunzelmann, N; Krieg, T; Moinzadeh, P	1
Akamata, K; Asano, Y; Hatano, M; Ichimura, Y; Kawashima, T; Kinugawa, K; Miyazaki, M; Noda, S; Sato, S; Sugita, M; Sumida, H; Takahashi, T; Tamaki, Z; Taniguchi, T; Tomita, M; Toyama, T; Yao, A	1
Kurgyis, Z; Lang, MU; Ruzicka, T; Sárdy, M; Sick, I; Varga, R	1
Furuya, Y; Kuwana, M	1
Hasegawa, M; Hattori, T; Ishikawa, O; Nagai, Y; Okada, E; Tago, O	1
Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N	1
Hoffmann, U; Kuhn, A; Riemekasten, G; Sunderkötter, C; Weiss, N	1
Stern, PJ; Wall, LB	1
Nishibu, A; Oyama, N; Sakai, E; Yamamoto, T	1
Bellando Randone, S; Bruni, C; Carnesecchi, G; Guiducci, S; Iannone, F; Lapadula, G; Maresta, A; Matucci Cerinic, M	1
Cutolo, M; Pizzorni, C; Smith, V; Sulli, A; Vremis, L; Zampogna, G	1
Gerry Coghlan, J; Humbert, M; Khanna, D	1
Celermajer, DS; Corte, TJ; Don, GW; Joseph, F	1
Brizzolara, R; Cutolo, M; Ferrone, C; Montagna, P; Parodio, A; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B	1
Cardarelli, S; Cozzi, F; Favaro, M; Pigatto, E; Punzi, L; Riato, L; Rizzo, M; Zanatta, E	1
Schachna, L; Wigley, FM	1
Cabane, J; Humbert, M	1
Varga, J	2
Korn, JH	1
Hachulla, E	1
Budde, K; Dingemanse, J; Hocher, B; Liefeldt, L; Neumayer, HH; Rudolph, B; van Giersbergen, PL; Walde, T	1
Coghlan, JG; Hachulla, E	1
Brito-Zerón, P; Claver, G; Fernandez, S; Font, J; Julià, M; Nardi, N; Parraga, FD; Ramos-Casals, M; Risco, G	1
Black, C; Carpentier, P; Chatterjee, S; Coppock, J; Denton, CP; Furst, D; Gaitonde, M; Guillevin, L; Hachulla, E; Herrick, A; Hsu, V; Korn, JH; Matucci Cerinic, M; Mayes, M; Merkel, PA; Molitor, J; Nguyen, N; Peter, HH; Pope, J; Rainisio, M; Rich, E; Seibold, JR; Simms, R	1
Ahmadi-Simab, K; Gross, WL; Hellmisch, B; Lamprecht, P	1
Antonaci, S; Giannelli, G; Iannone, F; Lapadula, G; Marinosci, F	2
Grau, RG; Jacobs, MR; Knox, KS; Snyder, MJ; Wilkes, DS	1
Girgis, RE; Hassoun, PM; Krishnan, JA; Mathai, SC; Wigley, FM	1
Akram, MR; Black, CM; Coghlan, JG; Das, C; Davar, J; Denton, CP; Handler, CE; Smith, CJ; Williams, MH	1
Kashour, T; Philipp, R; Sharma, S	1
Joglekar, A; McCloskey, DA; Riley, DJ; Seibold, JR; Tsai, FS; Wilson, JE	1
Riemekasten, G	1
Dunne, J; Dutz, J; Ng, B; Shojania, K; van Eeden, S	1
Cozzi, F; Favaro, M; Marotta, H; Ostuni, PA; Sfriso, P; Todesco, S	1
Boullanger, N; Carpentier, P; Diot, E; Fain, O; Hachulla, E; Hatron, PY; Jego, P; Launay, D; Mouthon, L; Pasquier, E	1
Chevallier, D; Hervé, F; Levesque, H; Marie, I; Muir, JF; Tillon, J	1
Hasegawa, A; Ishikawa, O; Nagai, Y; Nakano, A; Nishimura, S; Yamanaka, M	1
Lyseng-Williamson, KA; Oldfield, V	1
Black, CM; Denton, CP; Humbert, M; Rubin, L	1
Jain, M; Varga, J	1
Musch, A	1
McLaughlin, VV	1
Ahmadi-Simab, K; Gross, WL; Hellmich, B	1
Bobbo, F; Cozzi, F; Durigon, N; Iliceto, S; Marotta, H; Montisci, R; Ruscazio, M; Sfriso, P; Todesco, S	1
Beretta, L; Del Papa, N; Mazzone, A; Scorza, R	1
Duschek, N; Karlhofer, F; Minimair, G; Selenko-Gebauer, N; Stingl, G	1
Champion, HC; Fisher, MR; Girgis, RE; Hassoun, PM; Housten-Harris, T; Mathai, SC; Zaiman, A	1
Allanore, Y; Kahan, A; Legmann, P; Meune, C; Vignaux, O; Weber, S	1
Herrick, AL; Moore, TL; Vail, A	1
Hachulla, E; Humbert, M; Launay, D	1
Chamaillard, M; Constans, J; Heliot-Hosten, I; Taïeb, A	1
Hoeper, MM	1
Rösener, I; Rübben, A	1
Fain, O	1
Fragiadaki, KG; Katsichti, P; Mavrikakis, M; Papamichael, C; Sfikakis, PP; Stamatelopoulos, KS; Stefanadis, C; Tousoulis, D	1
Abraham, DJ; Black, CM; Bou-Gharios, G; Chen, Y; Dashwood, MR; Denton, CP; du Bois, RM; Howat, S; Kennedy, L; Leask, A; Pearson, JD; Renzoni, EA; Shi-Wen, X	1
Bootsma, H; Hettema, ME; Kallenberg, CG; Zhang, D	1
Humbert, M	1
Bizzoca, R; Cinelli, M; Guiducci, S; Iannone, F; Lapadula, G; Matucci-Cerinic, M; Riccardi, MT	1
Corrocher, R; Lippi, G; Lunardi, C; Montagnana, M; Prati, D; Puccetti, A; Simeoni, S; Tinazzi, E	1
Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Koliakos, G; Settas, L; Sfetsios, T	1
Distler, JH; Distler, O; Hoeper, MM	1
Beltrán Gutiérrez, J; Carmona, L; Díaz-Miguel, C; Gámir Gámir, ML; García de la Peña-Lefebvre, P; Orte Martínez, J; Rodríguez Rubio, S; Valero Expósito, M; Zea Mendoza, AC	1
Antonelli-Incalzi, R; Catapano-Minotti, G; Corsonello, A; Guadalupi, G; Spani, R	1
Badesch, DB; Bodin, F; Channick, RN; Frost, A; Rainisio, M; Robbins, IM; Roux, S; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF	1
Badesch, DB; Barst, RJ; Black, CM; Frost, A; Galie, N; Keogh, A; Landzberg, M; Leconte, I; Pulido, T; Roux, S; Rubin, LJ; Simonneau, G	1

Reviews

24 review(s) available for bosentan anhydrous and Sclerosis, Systemic

Article	Year
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. Rheumatology (Oxford, England), 2023, 12-01, Volume: 62, Issue:12 Topics: Adult; Bosentan; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer	2023
[Management of borderline pulmonary arterial hypertension associated with connective tissue diseases]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2014, Volume: 37, Issue:6 Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Disease Susceptibility; Diuretics; Early Diagnosis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Nitric Oxide Synthase Type II; Polymorphism, Genetic; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents	2014
Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. The international journal of biochemistry & cell biology, 2015, Volume: 67 Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelial Cells; Epigenesis, Genetic; Fibroblasts; Genetic Predisposition to Disease; Humans; Macrophages; Mice; Mice, Transgenic; Proto-Oncogene Protein c-fli-1; Scleroderma, Systemic; Sulfonamides; Th17 Cells; Th2 Cells	2015
Bosentan in systemic sclerosis. Drugs of today (Barcelona, Spain : 1998), 2008, Volume: 44, Issue:6 Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2008
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Drugs, 2008, Volume: 68, Issue:12 Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome	2008
Endothelin and scleroderma lung disease. Rheumatology (Oxford, England), 2008, Volume: 47 Suppl 5 Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Lung Diseases, Interstitial; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Transforming Growth Factor beta; Treatment Failure	2008
Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford, England), 2008, Volume: 47 Suppl 5 Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Ischemia; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasodilator Agents	2008
[Pulmonary arterial hypertension related to systemic sclerosis in 2008]. Journal des maladies vasculaires, 2009, Volume: 34, Issue:1 Topics: Altitude; Antihypertensive Agents; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; France; Humans; Hypertension, Pulmonary; Hypoxia; Oxygen; Phosphodiesterase 5 Inhibitors; Prognosis; Scleroderma, Systemic; Sulfonamides	2009
Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford, England), 2009, Volume: 48 Suppl 3 Topics: Antihypertensive Agents; Bosentan; Databases, Factual; Endothelium, Vascular; Fingers; Hand Dermatoses; Humans; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2009
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford, England), 2009, Volume: 48 Suppl 3 Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Exercise Tolerance; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones	2009
Vasculopathy and pulmonary arterial hypertension. Rheumatology (Oxford, England), 2009, Volume: 48 Suppl 3 Topics: Antihypertensive Agents; Bosentan; Churg-Strauss Syndrome; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sjogren's Syndrome; Sulfonamides; Vasculitis	2009
Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs, 2009, Oct-01, Volume: 69, Issue:14 Topics: Bosentan; Drug Interactions; Endothelin A Receptor Antagonists; Endothelium, Vascular; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome	2009
Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan. Annals of the rheumatic diseases, 2010, Volume: 69, Issue:11 Topics: Antihypertensive Agents; Bosentan; Disability Evaluation; Fingers; Hand Dermatoses; Humans; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2010
Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Joint bone spine, 2011, Volume: 78, Issue:4 Topics: Bosentan; Calcium Channel Blockers; Cardiovascular Agents; Endothelin Receptor Antagonists; Enzyme Inhibitors; Fingers; Humans; Phosphodiesterase 5 Inhibitors; Prostaglandins I; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents	2011
Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflammation & allergy drug targets, 2011, Volume: 10, Issue:1 Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome	2011
[Management of digital ulcers in patients with systemic sclerosis]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:1-2 Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Ischemia; Male; Raynaud Disease; Risk Factors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents	2012
Early detection and management of pulmonary arterial hypertension. European respiratory review : an official journal of the European Respiratory Society, 2012, Dec-01, Volume: 21, Issue:126 Topics: Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Early Diagnosis; Echocardiography, Doppler; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Practice Guidelines as Topic; Purines; Respiratory Function Tests; Risk Factors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents	2012
Targeting mediators of vascular injury in scleroderma. Current opinion in rheumatology, 2002, Volume: 14, Issue:6 Topics: Antihypertensive Agents; Biomarkers; Bosentan; Clinical Trials as Topic; Endothelin-1; Endothelium, Vascular; Epoprostenol; Humans; Hypertension, Pulmonary; Muscle, Smooth, Vascular; Reactive Oxygen Species; Scleroderma, Systemic; Sulfonamides	2002
[Treatment of pulmonary arterial hypertension associated to systemic sclerosis]. La Revue de medecine interne, 2004, Volume: 25, Issue:3 Topics: Antihypertensive Agents; Bosentan; Calcium; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Scleroderma, Systemic; Sulfonamides	2004
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Annals of the rheumatic diseases, 2004, Volume: 63, Issue:9 Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Sulfonamides	2004
Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:3 Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides	2006
Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:11 Topics: Animals; Bosentan; Drug Tolerance; Humans; Hypertension; Pulmonary Fibrosis; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2006
[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:7 Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides	2006
[Pulmonary arterial hypertension and systemic sclerosis]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:12 Pt 2 Topics: Algorithms; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cohort Studies; Echocardiography, Doppler; Epoprostenol; European Union; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Prognosis; Purines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents; World Health Organization	2006

Trials

29 trial(s) available for bosentan anhydrous and Sclerosis, Systemic

Article	Year
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey. Arthritis research & therapy, 2019, 01-24, Volume: 21, Issue:1 Topics: Adult; Bosentan; Calcium Channel Blockers; Drug Therapy, Combination; European Union; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Surveys and Questionnaires	2019
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. Clinical rheumatology, 2020, Volume: 39, Issue:1 Topics: Adult; Aged; Bosentan; Drug Therapy, Combination; Europe; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Treatment Outcome; Vasodilator Agents; Wound Healing	2020
Influence of bosentan on fingertip rewarming in patients with systemic sclerosis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Female; Fingers; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin; Skin Temperature; Sulfonamides; Treatment Outcome	2013
Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin. European journal of medical research, 2014, Jan-10, Volume: 19 Topics: Adult; Aged; Aged, 80 and over; Bosentan; Face; Female; Humans; Iloprost; Linear Models; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Telangiectasis	2014
Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. The Journal of rheumatology, 2014, Volume: 41, Issue:5 Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Laser-Doppler Flowmetry; Male; Microscopic Angioscopy; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents	2014
[Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases]. Terapevticheskii arkhiv, 2014, Volume: 86, Issue:5 Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Survival Rate; Treatment Outcome	2014
Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan. Rheumatology (Oxford, England), 2015, Volume: 54, Issue:2 Topics: Adult; Aged; Analysis of Variance; Bosentan; Case-Control Studies; Drug Administration Schedule; Female; Hand; Humans; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasodilator Agents	2015
[Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis]. Terapevticheskii arkhiv, 2015, Volume: 87, Issue:1 Topics: Antihypertensive Agents; Biomarkers; Bosentan; Cardiac Catheterization; Echocardiography; Exercise; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Circulation; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2015
Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. The Journal of dermatology, 2017, Volume: 44, Issue:1 Topics: Administration, Oral; Adult; Aged; Anemia; Arthralgia; Bosentan; Constipation; Diarrhea; Endothelin Receptor Antagonists; Female; Fingers; Herpes Zoster; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing	2017
Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatology international, 2009, Volume: 29, Issue:7 Topics: Adult; Aged; Antihypertensive Agents; Arteries; Bosentan; Connective Tissue Diseases; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Mixed Connective Tissue Disease; Prospective Studies; Pulmonary Artery; Raynaud Disease; Scleroderma, Systemic; Skin Diseases; Sulfonamides; Ulcer; Vasculitis	2009
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford, England), 2010, Volume: 49, Issue:3 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Epidemiologic Methods; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome	2010
Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford, England), 2010, Volume: 49, Issue:3 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Endothelin Receptor Antagonists; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2010
Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford, England), 2010, Volume: 49, Issue:7 Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fibrosis; Humans; Male; Middle Aged; Receptors, Endothelin; Scleroderma, Systemic; Skin Ulcer; Statistics as Topic; Sulfonamides; Treatment Outcome	2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis and rheumatism, 2010, Volume: 62, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Comorbidity; Double-Blind Method; Exercise Test; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Quality of Life; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides; Survival Rate; Young Adult	2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases, 2011, Volume: 70, Issue:1 Topics: Adult; Bosentan; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Fingers; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing	2011
Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. The Journal of rheumatology, 2010, Volume: 37, Issue:12 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Laser-Doppler Flowmetry; Male; Middle Aged; Raynaud Disease; Regional Blood Flow; Scleroderma, Systemic; Skin; Sulfonamides	2010
Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis and rheumatism, 2012, Volume: 64, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Exercise Test; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Middle Aged; Pilot Projects; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2012
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis and rheumatism, 2004, Volume: 50, Issue:12 Topics: Activities of Daily Living; Administration, Oral; Antihypertensive Agents; Bosentan; Disability Evaluation; Double-Blind Method; Endothelin Receptor Antagonists; Female; Fingers; Health Status; Humans; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Surveys and Questionnaires; Treatment Outcome	2004
New hope for systemic sclerosis patients with digital ulcers. Current rheumatology reports, 2005, Volume: 7, Issue:2 Topics: Administration, Oral; Bosentan; Chemical and Drug Induced Liver Injury; Double-Blind Method; Endothelin Receptor Antagonists; Fingers; Foot Dermatoses; Hand Dermatoses; Humans; Scleroderma, Localized; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Toes; Treatment Outcome	2005
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Current medical research and opinion, 2005, Volume: 21, Issue:3 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Scleroderma, Systemic; Sulfonamides	2005
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Annals of the rheumatic diseases, 2006, Volume: 65, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin A Receptor Antagonists; Epidemiologic Methods; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2006
Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. European journal of clinical investigation, 2006, Volume: 36 Suppl 3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2006
Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford, England), 2006, Volume: 45 Suppl 3 Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides; Treatment Outcome	2006
Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. The Journal of rheumatology, 2006, Volume: 33, Issue:12 Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Coronary Circulation; Echocardiography, Doppler; Heart; Humans; Magnetic Resonance Imaging; Middle Aged; Myocardial Contraction; Scleroderma, Systemic; Sulfonamides	2006
Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:2 Topics: Adult; Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Male; Microcirculation; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2007
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis and rheumatism, 2007, Volume: 56, Issue:6 Topics: Administration, Oral; Adult; Aged; Bosentan; Brachial Artery; Dose-Response Relationship, Drug; E-Selectin; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Female; Humans; Hypertension, Pulmonary; Intercellular Adhesion Molecule-1; Male; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Ultrasonography; Vascular Endothelial Growth Factor A; Vasodilation	2007
Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford, England), 2008, Volume: 47, Issue:4 Topics: Adolescent; Adult; Aged; Bosentan; Child; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome	2008
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (London, England), 2001, Oct-06, Volume: 358, Issue:9288 Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Exercise; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2001
Bosentan therapy for pulmonary arterial hypertension. The New England journal of medicine, 2002, Mar-21, Volume: 346, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Liver; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Walking	2002

Other Studies

111 other study(ies) available for bosentan anhydrous and Sclerosis, Systemic

Article	Year
Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan. Acta dermato-venereologica, 2021, Nov-24, Volume: 101, Issue:11 Topics: Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Esophagitis, Peptic; Humans; Pharmaceutical Preparations; Pyrroles; Scleroderma, Systemic; Sulfonamides; Ulcer	2021
Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study. The Journal of dermatology, 2023, Volume: 50, Issue:6 Topics: Bosentan; East Asian People; Humans; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome	2023
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. International heart journal, 2020, Volume: 61, Issue:2 Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents	2020
Pulse Wave Velocity in Systemic Sclerosis: Potential Beneficial Effects of Bosentan on Forearm Arterial Stiffness? An Exploratory Study. The Journal of rheumatology, 2021, 01-01, Volume: 48, Issue:1 Topics: Blood Flow Velocity; Blood Pressure; Bosentan; Forearm; Humans; Pulse Wave Analysis; Scleroderma, Systemic; Vascular Stiffness	2021
Novel Use of Bosentan for Postoperative Wound Healing of the Foot in Systemic Sclerosis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8S Topics: Bosentan; Humans; Scleroderma, Systemic; Skin Ulcer; Wound Healing	2021
Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. PloS one, 2020, Volume: 15, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Case-Control Studies; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome; Ulcer	2020
Effects of Bosentan in the Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: A Longitudinal, Multicenter, Uncontrolled Trial. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8 Topics: Bosentan; Fingers; Humans; Republic of Korea; Scleroderma, Systemic; Skin Ulcer; Ulcer	2021
Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report. Medicine, 2017, Volume: 96, Issue:25 Topics: Bosentan; Cardiovascular Agents; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Peripheral Arterial Disease; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides	2017
Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome. Revista da Associacao Medica Brasileira (1992), 2017, Volume: 63, Issue:5 Topics: Aged; Aged, 80 and over; Alprostadil; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Fingers; Hand Dermatoses; Humans; Male; Middle Aged; Reproducibility of Results; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Wound Healing	2017
Assessment of treatment effects on digital ulcer and blood perfusion by laser speckle contrast analysis in a patient affected by systemic sclerosis. Reumatismo, 2017, Sep-21, Volume: 69, Issue:3 Topics: Bosentan; Female; Fingers; Humans; Iloprost; Lasers; Methotrexate; Microcirculation; Microscopic Angioscopy; Middle Aged; para-Aminobenzoates; Raynaud Disease; Scattering, Radiation; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tramadol; Treatment Outcome	2017
Systemic sclerosis: severe pulmonary arterial hypertension and pericardial effusion at diagnosis. BMJ case reports, 2018, May-14, Volume: 2018 Topics: Bosentan; Calcium Channel Blockers; Chest Pain; Diagnostic Errors; Diltiazem; Echocardiography; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Lung; Microscopic Angioscopy; Middle Aged; Pericardial Effusion; Pericarditis; Scleroderma, Systemic; Sulfonamides; Tomography, X-Ray Computed	2018
A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis. Experimental dermatology, 2019, Volume: 28, Issue:5 Topics: Aged; Biomarkers; Bosentan; Endothelin Receptor Antagonists; Epithelium; Esophageal Diseases; Female; Galectins; Gene Expression Regulation; Humans; Keratinocytes; Male; Middle Aged; Pigmentation; Scleroderma, Systemic; Skin	2019
Systemic capillary leak syndrome following bosentan treatment in a patient with systemic sclerosis. Scandinavian journal of rheumatology, 2019, Volume: 48, Issue:5 Topics: Bosentan; Capillary Leak Syndrome; Endothelin Receptor Antagonists; Humans; Male; Middle Aged; Scleroderma, Systemic; Ultrasonography	2019
Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:9 Topics: Acute Kidney Injury; Adult; Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Endothelin-1; Female; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Receptor, Endothelin A; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2013
Endothelin receptor antagonism-based treatment for scleroderma renal crisis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 62, Issue:2 Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Renal Insufficiency, Chronic; Scleroderma, Systemic; Sulfonamides	2013
Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers. Reumatismo, 2013, May-27, Volume: 65, Issue:2 Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Remission Induction; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Sulfones	2013
Pulmonary hypertension complicating connective tissue disease. Seminars in respiratory and critical care medicine, 2013, Volume: 34, Issue:5 Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Lung Transplantation; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pyridazines; Scleroderma, Systemic; Sulfonamides	2013
Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatology international, 2014, Volume: 34, Issue:2 Topics: Aged; Antihypertensive Agents; Biomarkers; Bosentan; Endothelin-1; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nitric Oxide; Prospective Studies; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome	2014
In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension. Rheumatology (Oxford, England), 2014, Volume: 53, Issue:3 Topics: Bosentan; Cardiovascular Agents; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fingers; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome	2014
Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists. BMJ case reports, 2014, Mar-28, Volume: 2014 Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vascular Diseases	2014
Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis research & therapy, 2014, Apr-03, Volume: 16, Issue:2 Topics: Animals; Bosentan; Chromatin Immunoprecipitation; Collagen Type I; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibroblasts; Fibrosis; Humans; Immunoblotting; Mice; Phenotype; Proto-Oncogene Protein c-fli-1; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Scleroderma, Systemic; Signal Transduction; Skin; Sulfonamides	2014
Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval. Scandinavian journal of rheumatology, 2014, Volume: 43, Issue:5 Topics: Adult; Aged; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Fingers; France; Humans; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Smoking; Sulfonamides; Treatment Outcome; Ulcer	2014
Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective. The New Zealand medical journal, 2014, Aug-15, Volume: 127, Issue:1400 Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Electrocardiography; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; New Zealand; Physical Examination; Piperazines; Practice Patterns, Physicians'; Purines; Respiratory Function Tests; Rheumatology; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires; Vasodilator Agents	2014
[Digital ulcers in systemic scleroderma]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014, Volume: 65, Issue:11 Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Wound Healing	2014
Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts. The Journal of rheumatology, 2015, Volume: 42, Issue:3 Topics: Actins; Aged; Bosentan; Down-Regulation; Endothelin A Receptor Antagonists; Female; Fibroblasts; Humans; Male; Middle Aged; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides	2015
Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:5 Topics: Actins; Animals; Bosentan; Capillary Permeability; Cell Line; Cells, Cultured; Chromatin Immunoprecipitation; Endothelial Cells; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression; Humans; Immunoblotting; Immunohistochemistry; Mice; Mice, Knockout; Microvessels; Phosphorylation; Promoter Regions, Genetic; Protein Kinase C-delta; Proto-Oncogene Protein c-fli-1; Proto-Oncogene Proteins c-abl; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Scleroderma, Systemic; Sulfonamides; Vascular Diseases	2015
Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis. Journal of immunology research, 2015, Volume: 2015 Topics: Anti-Inflammatory Agents; Bosentan; CD4-Positive T-Lymphocytes; Endothelin Receptor Antagonists; Endothelin-1; Female; Fibroblasts; Fibrosis; Humans; Inflammation; Interferon-gamma; Male; Middle Aged; Monocytes; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides	2015
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. International journal of rheumatic diseases, 2017, Volume: 20, Issue:1 Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Up-Regulation	2017
Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy. The Israel Medical Association journal : IMAJ, 2015, Volume: 17, Issue:2 Topics: Adenocarcinoma; Aged; Biopsy, Fine-Needle; Bosentan; Diagnosis, Differential; Endothelin Receptor Antagonists; Female; Fingers; Humans; Lung Neoplasms; Neoplasm Staging; Paraneoplastic Syndromes; Pneumonectomy; Scleroderma, Systemic; Serologic Tests; Skin Ulcer; Sulfonamides; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed; Treatment Outcome	2015
Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions. The British journal of dermatology, 2016, Volume: 174, Issue:2 Topics: Adult; Aged; alpha-2-Antiplasmin; Analysis of Variance; Animals; Antigens, CD; Bleomycin; Bosentan; Case-Control Studies; Cells, Cultured; Down-Regulation; Endothelial Cells; Endothelial Protein C Receptor; Endothelin Receptor Antagonists; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysin; Humans; Male; Mice; Microvessels; Middle Aged; Proto-Oncogene Protein c-fli-1; Receptors, Cell Surface; Scleroderma, Systemic; Sulfonamides; Thrombophilia	2016
Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. Clinical rheumatology, 2016, Volume: 35, Issue:1 Topics: Adult; Aged; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents	2016
Digital ulcers in scleroderma patients: A retrospective observational study. International journal of immunopathology and pharmacology, 2016, Volume: 29, Issue:2 Topics: Adult; Bosentan; Female; Fingers; Humans; Iloprost; Leg; Male; Middle Aged; Retrospective Studies; Scleroderma, Localized; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing	2016
Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis. Modern rheumatology, 2017, Volume: 27, Issue:1 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2017
[Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies]. Zeitschrift fur Rheumatologie, 2017, Volume: 76, Issue:3 Topics: Adult; Bosentan; Female; Fingers; Germany; Guideline Adherence; Health Care Surveys; Humans; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasoconstrictor Agents; Young Adult	2017
Bosentan for digital ulcers prevention does not worsen cardiopulmonary exercise test parameters in SSc patients with interstitial lung disease. International journal of cardiology, 2016, Nov-15, Volume: 223 Topics: Adult; Bosentan; Disease Progression; Endothelin Receptor Antagonists; Exercise Test; Female; Fingers; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Receptor, Endothelin A; Respiratory Function Tests; Scleroderma, Systemic; Skin Ulcer; Statistics as Topic; Sulfonamides; Treatment Outcome	2016
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis research & therapy, 2016, 10-06, Volume: 18, Issue:1 Topics: Adult; Aged; Blotting, Western; Bosentan; Cell Transdifferentiation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Endothelin Receptor Antagonists; Female; Fibroblasts; Humans; In Vitro Techniques; Middle Aged; Myofibroblasts; Pyrimidines; Real-Time Polymerase Chain Reaction; Scleroderma, Systemic; Sulfonamides	2016
Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. The Journal of rheumatology, 2016, Volume: 43, Issue:11 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Fingers; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Vasodilator Agents	2016
Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:6 Topics: Adult; Aged; Bosentan; Disability Evaluation; Endothelin Receptor Antagonists; Female; Hand; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome	2017
Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case. International wound journal, 2017, Volume: 14, Issue:6 Topics: Administration, Intravenous; Administration, Oral; Bosentan; Botulinum Toxins, Type A; Cross-Sectional Studies; Female; Fingers; Humans; Iloprost; Middle Aged; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing	2017
[Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis]. Harefuah, 2008, Volume: 147, Issue:4 Topics: Antihypertensive Agents; Bosentan; Endothelin-1; Fatal Outcome; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Scleroderma, Systemic; Sulfonamides	2008
N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatology international, 2009, Volume: 29, Issue:3 Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides	2009
Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma. Annals of the rheumatic diseases, 2008, Volume: 67, Issue:12 Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Leg Ulcer; Middle Aged; Scleroderma, Systemic; Sulfonamides	2008
Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1. Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:6 Topics: Acetylcholine; Animals; Bosentan; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Prostaglandins; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Vasodilation; Vasodilator Agents	2008
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis and rheumatism, 2009, Volume: 60, Issue:2 Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents	2009
Delayed hypersensitivity to bosentan. Allergy, 2009, Volume: 64, Issue:3 Topics: Adult; Antihypertensive Agents; Betamethasone; Bosentan; Exanthema; Female; Glucocorticoids; Humans; Hypersensitivity, Delayed; Hypertension, Pulmonary; Lymphocyte Activation; Scleroderma, Systemic; Skin Tests; Sulfonamides	2009
Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009, Volume: 15, Issue:2 Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Drug Interactions; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Polypharmacy; Scleroderma, Systemic; Sulfonamides	2009
Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension. Journal of dermatological science, 2009, Volume: 55, Issue:1 Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Cytokines; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Interleukin-12; Male; Middle Aged; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides	2009
Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. The Journal of rheumatology, 2009, Volume: 36, Issue:7 Topics: Aged; Antihypertensive Agents; Biopsy; Bosentan; Female; Fingers; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Skin; Skin Ulcer; Sulfonamides; Treatment Outcome	2009
Graves' disease associated with primary systemic sclerosis. Orbit (Amsterdam, Netherlands), 2009, Volume: 28, Issue:4 Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves Disease; Humans; Hypertension, Pulmonary; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Proteinuria; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2009
Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Aged; Anti-Bacterial Agents; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingers; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2010
Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. The Journal of rheumatology, 2010, Volume: 37, Issue:5 Topics: Aged; Anti-Ulcer Agents; Bosentan; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; Fever; Humans; Scleroderma, Systemic; Sulfonamides; Syndrome	2010
A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al. Arthritis and rheumatism, 2010, Volume: 62, Issue:10 Topics: Antihypertensive Agents; Bosentan; Endothelins; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2010
Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis. Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:21 Topics: Bosentan; Exercise; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Scleroderma, Systemic; Sulfonamides	2010
[Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2010, Volume: 48, Issue:10 Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents	2010
Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Annals of the rheumatic diseases, 2011, Volume: 70, Issue:8 Topics: Adult; Aged; Biopsy; Bosentan; Case-Control Studies; CD4-Positive T-Lymphocytes; Dermatitis; Dermatologic Agents; Endothelin A Receptor Antagonists; Female; Forkhead Transcription Factors; Humans; Immune Tolerance; Male; Middle Aged; Scleroderma, Localized; Scleroderma, Systemic; Skin; Sulfonamides; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory	2011
Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis. Nature reviews. Rheumatology, 2011, Volume: 7, Issue:1 Topics: Bosentan; Diarrhea; Endothelin Receptor Antagonists; Fingers; Hand; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Transaminases; Treatment Outcome	2011
[A complication of coronary angiography in a female patient with systemic sclerosis]. Nederlands tijdschrift voor geneeskunde, 2011, Volume: 155 Topics: Aged; Antihypertensive Agents; Arterial Occlusive Diseases; Bosentan; Coronary Angiography; Female; Humans; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2011
Bosentan improves systemic sclerosis-related peripheral circulation insufficiency. International journal of cardiology, 2011, Mar-17, Volume: 147, Issue:3 Topics: Adult; Aged; Blood Circulation; Bosentan; Female; Humans; Middle Aged; Pain Measurement; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2011
Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. The Journal of rheumatology, 2011, Volume: 38, Issue:7 Topics: Bosentan; Canada; Epoprostenol; Europe; Health Surveys; Humans; Hypertension, Pulmonary; Iloprost; Methotrexate; North America; Practice Guidelines as Topic; Scleroderma, Systemic; Skin Diseases; Societies, Medical; Sulfonamides; Treatment Outcome; Vascular Diseases	2011
Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. The Journal of rheumatology, 2011, Volume: 38, Issue:8 Topics: Antihypertensive Agents; Bosentan; Cohort Studies; Humans; Hypertension; Ischemia; Randomized Controlled Trials as Topic; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Spain; Sulfonamides; Treatment Outcome	2011
Chronic leg ulceration as the presenting feature of diffuse systemic sclerosis in childhood. The Journal of pediatrics, 2011, Volume: 159, Issue:4 Topics: Adolescent; Bosentan; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Leg Ulcer; Nifedipine; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents	2011
Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis. Pediatric cardiology, 2011, Volume: 32, Issue:7 Topics: Antihypertensive Agents; Bosentan; Child; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Pulmonary Wedge Pressure; Scleroderma, Systemic; Sulfonamides; Thermography; Vascular Resistance	2011
Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers. International angiology : a journal of the International Union of Angiology, 2011, Volume: 30, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bosentan; Drug Therapy, Combination; Female; Fingers; Humans; Iloprost; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Wound Healing; Young Adult	2011
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:3 Topics: Bosentan; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Fingers; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Sulfones	2011
Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. The British journal of dermatology, 2012, Volume: 166, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dermatologic Agents; Female; Foot Ulcer; Humans; Hypertension, Pulmonary; Middle Aged; Off-Label Use; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Wound Healing	2012
Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis. Acta dermato-venereologica, 2011, Volume: 91, Issue:6 Topics: Antihypertensive Agents; Bosentan; Female; Hand Dermatoses; Humans; Keratosis; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2011
Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. The Journal of rheumatology, 2011, Volume: 38, Issue:10 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cyclophosphamide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2011
Bosentan for digital ulcers in patients with systemic sclerosis. The Journal of dermatology, 2012, Volume: 39, Issue:1 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Female; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Young Adult	2012
Nonoperative treatment of digital ischemia in systemic sclerosis. The Journal of hand surgery, 2012, Volume: 37, Issue:9 Topics: Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Education, Medical, Continuing; Endothelin Receptor Antagonists; Evidence-Based Medicine; Female; Fingers; Humans; Iloprost; Ischemia; Life Style; Middle Aged; Orthopedics; Phosphodiesterase 5 Inhibitors; Prostaglandins; Randomized Controlled Trials as Topic; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Vascular Resistance; Vasodilator Agents	2012
Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis. The Australasian journal of dermatology, 2012, Volume: 53, Issue:2 Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2012
Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clinical rheumatology, 2012, Volume: 31, Issue:12 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Capillaries; Female; Humans; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Young Adult	2012
Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. The Journal of rheumatology, 2013, Volume: 40, Issue:1 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Iloprost; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2013
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. Internal medicine journal, 2012, Volume: 42, Issue:12 Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes	2012
Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients. Reumatismo, 2012, Dec-11, Volume: 64, Issue:5 Topics: Aged; Bosentan; Cells, Cultured; Collagen Type I; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Extracellular Matrix Proteins; Female; Fibrillin-1; Fibrillins; Fibroblasts; Fibronectins; Fibrosis; Humans; Isoxazoles; Microfilament Proteins; Middle Aged; Primary Cell Culture; Scleroderma, Systemic; Sulfonamides; Thiophenes	2012
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clinical rheumatology, 2013, Volume: 32, Issue:5 Topics: Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vascular Diseases	2013
Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford, England), 2003, Volume: 42, Issue:1 Topics: Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2003
Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis. Current rheumatology reports, 2003, Volume: 5, Issue:2 Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Lung; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2003
Scleroderma: a treatable disease. Cleveland Clinic journal of medicine, 2003, Volume: 70, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bosentan; Humans; Pulmonary Fibrosis; Scleroderma, Systemic; Sulfonamides	2003
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 43, Issue:5 Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Kidney Failure, Chronic; Scleroderma, Systemic; Sulfonamides	2004
Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford, England), 2004, Volume: 43, Issue:11 Topics: Adult; Bosentan; Female; Humans; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2004
[Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience]. Zeitschrift fur Rheumatologie, 2004, Volume: 63, Issue:6 Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Physical Endurance; Pilot Projects; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2004
Resolution of severe digital ulceration during a course of Bosentan therapy. Annals of internal medicine, 2005, May-03, Volume: 142, Issue:9 Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides	2005
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2005, Volume: 24, Issue:10 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome	2005
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (British Cardiac Society), 2006, Volume: 92, Issue:7 Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Prostaglandins; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Vasodilator Agents	2006
Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Texas Heart Institute journal, 2005, Volume: 32, Issue:3 Topics: Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Pulmonary Wedge Pressure; Receptors, Endothelin; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Sulfonamides; Thromboembolism	2005
Bosentan in pulmonary arterial hypertension secondary to scleroderma. The Journal of rheumatology, 2006, Volume: 33, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Respiratory Function Tests; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2006
[Endothelin receptor antagonism in routine clinical care]. Krankenpflege Journal, 2005, Volume: 43, Issue:7-10 Topics: Bosentan; Controlled Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Prognosis; Scleroderma, Systemic; Sulfonamides; Survival Analysis	2005
Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis. Rheumatology (Oxford, England), 2006, Volume: 45, Issue:7 Topics: Adult; Bosentan; Female; Fingers; Gangrene; Humans; Raynaud Disease; Scleroderma, Systemic; Sulfonamides	2006
Bosentan may induce arthritis flare in patients with scleroderma concomitantly treated with methotrexate. Annals of the rheumatic diseases, 2006, Volume: 65, Issue:5 Topics: Antihypertensive Agents; Arthritis; Bosentan; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Scleroderma, Systemic; Sulfonamides	2006
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:4 Pt 1 Topics: Adult; Aged; Antibodies, Antinuclear; Bosentan; Endothelin-1; Female; Fingers; Follow-Up Studies; Humans; Ischemia; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome	2006
Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. The British journal of dermatology, 2006, Volume: 154, Issue:5 Topics: Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Middle Aged; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tomography, X-Ray Computed	2006
Drug eruption due to bosentan in a patient with systemic sclerosis. Modern rheumatology, 2006, Volume: 16, Issue:3 Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Drug Eruptions; Endothelin Receptor Antagonists; Eosinophilia; Female; Humans; Hypertension, Pulmonary; Middle Aged; Prednisolone; Scleroderma, Systemic; Sulfonamides	2006
Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. European journal of clinical investigation, 2006, Volume: 36 Suppl 3 Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pulmonary Fibrosis; Scleroderma, Systemic; Sulfonamides; Walking	2006
Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. European journal of clinical investigation, 2006, Volume: 36 Suppl 3 Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Connective Tissue Diseases; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Myositis; Prospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Right; Walking	2006
Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. European journal of clinical investigation, 2006, Volume: 36 Suppl 3 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Treatment Outcome	2006
Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost. The Journal of rheumatology, 2006, Volume: 33, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Respiratory Function Tests; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2006
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. The European respiratory journal, 2007, Volume: 29, Issue:3 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Volume Measurements; Male; Middle Aged; Piperazines; Pulmonary Wedge Pressure; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents	2007
[Systemic sclerosis: paths into the future]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:12 Pt 2 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Forecasting; Humans; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Prostaglandins I; Purines; Quality of Life; Research; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents	2006
Bosentan as a rescue therapy in scleroderma refractory digital ulcers. Archives of dermatology, 2007, Volume: 143, Issue:1 Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome	2007
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value. The European respiratory journal, 2007, Volume: 29, Issue:3 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents	2007
[Treatment of a leg ulcer with bosentan in a female patient with progressive systemic scleroderma]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2007, Volume: 58, Issue:5 Topics: Administration, Oral; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Scleroderma, Systemic; Sulfonamides; Varicose Ulcer	2007
[Digital necrosis in scleroderma]. La Revue du praticien, 2007, Feb-28, Volume: 57, Issue:4 Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Necrosis; Platelet Aggregation Inhibitors; Recurrence; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents	2007
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix biology : journal of the International Society for Matrix Biology, 2007, Volume: 26, Issue:8 Topics: Biopsy; Bosentan; Cell Adhesion; Cells, Cultured; Collagen Type I; Connective Tissue Growth Factor; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fibroblasts; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Scleroderma, Systemic; Signal Transduction; Sulfonamides	2007
Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:10 Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome	2007
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma]. La Revue de medecine interne, 2007, Volume: 28 Suppl 4 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Phosphodiesterase Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents	2007
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Annals of the rheumatic diseases, 2008, Volume: 67, Issue:8 Topics: Adult; Aged; Analysis of Variance; Antibodies, Antinuclear; Antihypertensive Agents; Autoantibodies; Bosentan; Case-Control Studies; CD3 Complex; Cell Adhesion Molecules; Centromere; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Integrin alpha4beta1; L-Selectin; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; T-Lymphocytes	2008
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatology international, 2008, Volume: 28, Issue:7 Topics: Adult; Aged; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides	2008
N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clinical rheumatology, 2008, Volume: 27, Issue:5 Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides	2008
Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. Nature clinical practice. Rheumatology, 2008, Volume: 4, Issue:3 Topics: Adult; Antihypertensive Agents; Bosentan; Dyspnea; Echocardiography; Exercise Test; Female; Humans; Hypertension, Pulmonary; Natriuretic Peptide, Brain; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides	2008
[Digital ulcers in systemic sclerosis]. Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:4 Pt 2 Topics: Bosentan; Fingers; Humans; Iloprost; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents	2008
Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:6 Topics: Bosentan; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents	2008